# CMDGA

- **Website:** <https://cmdga.org>
- **Primary alias:** `cmdga.org`

## Description

The Accelerating Medicines Partnership in Common Metabolic Diseases (AMP-CMD) is a pivotal consortium that unites leading organizations including the NIDDK, FNIH, Amgen, Eli Lilly and Company, Novo Nordisk, and Pfizer Inc., along with academic and non-profit researchers. Based at the University of California San Diego, this initiative focuses on advancing research in common metabolic diseases through the development of the Common Metabolic Diseases Genome Atlas (CMDGA). 

The CMDGA serves as a comprehensive resource that enhances understanding and treatment of prevalent conditions, including type 2 diabetes. Utilizing innovative software from the ENCODE DCC at Stanford University, the project aims to integrate data from multiple sources to foster collaboration and drive impactful insights into metabolic disorders. Furthermore, it features a user-friendly Common Metabolic Diseases Knowledge Portal and links to additional resources such as the Type 2 Diabetes Knowledge Portal. Funded by NIDDK, AMP-CMD represents a significant step forward in collaborative research that bridges academia and industry to combat metabolic diseases.

## Industries

- ⛑ Health
- ⛑ Biotechnology and Pharmaceuticals _(under Health)_
- 🧪 Science and Education
- 🧪 Biology _(under Science and Education)_

## Colors

| Name | Hex | Theme |
| --- | --- | --- |
| Science Blue | #0062c3 | accent |
| Niagara | #0bc07b | dark |
| Steel Blue | #5778b8 | light |

## Fonts

- Helvetica Neue — asset _(custom)_

---

_Source: <https://brandfetch.com/cmdga.org>_
_See [/llms.txt](/llms.txt) for a full list of agent-readable pages, and [/auth.md](/auth.md) for how agents authenticate._